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Abstract
Background: People with severe mental disorders (SMD) experience premature mortality mostly from preventable
physical causes. The World Health Organization (WHO) have recently produced guidelines on the management of
physical health conditions in SMD. This paper presents the evidence which led to the recommendations for
tobacco cessation and management of substance use disorders in SMD.
Methods: Scoping reviews informed 2 PICO (Population Intervention, Comparator, Outcome) questions relating to
tobacco cessation and management of substance use disorders in SMD. Systematic searches led to the
identification of systematic reviews with relevant evidence to address these questions. Retrieved evidence was
assessed using GRADE methodology, informing the development of guidelines.
Results: One thousand four hundred thirty-four records were identified through systematic searches for SMD and
tobacco cessation, of which 4 reviews were included in GRADE tables and 18 reviews in narrative synthesis. For
SMD and substance use disorders, 4268 records were identified, of which 4 studies from reviews were included in
GRADE tables and 16 studies in narrative synthesis.
People with SMD who use tobacco should be offered combined pharmacological (Varenicline, Bupropion or Nicotine
Replacement Therapy) and non-pharmacological interventions such as tailored directive and supportive behavioural
interventions. For people with SMD and substance use disorders (drug and/or alcohol), interventions should be
considered in accordance with WHO mhGAP guidelines. Prescribers should note potential drug-drug interactions.
Recommendation were conditional and based on low/very low certainty of evidence with a scarcity of evidence from
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low- and middle-income settings.
Conclusions: These guidelines mark an important step towards addressing premature mortality in people with SMD.
The dearth of high-quality evidence and evidence from LMIC settings must inform the future research agenda.
Guidelines: https://www.who.int/mental_health/evidence/guidelines_physical_health_and_severe_mental_disorders/en
https://www.who.int/publications-detail/mhgap-intervention-guide%2D%2D-version-2.0
Keywords: Severe mental illness, Schizophrenia, Bipolar affective disorders, Depression, Life expectancy, Mortality,
Ethnicity, Deprivation, Schizoaffective disorders, Serious mental illness
Background
The severe mental disorders (SMD), defined as
schizophrenia-spectrum, psychoses and bipolar disorders as
well as moderate to severe depression, are associated with
markedly reduced life expectancy [1]. Worldwide, reductions
in life expectancy amongst people with SMD are stark, ran-
ging from 11 to 17 years in the UK [2], 15–20 years across
Nordic countries [3], and up to 30 years reduced in low- and
middle-income country (LMIC) settings such as in Ethiopia
[4]. In particular, this decrement in life expectancy has been
noted to be increasing over time [5].
Although deaths from suicide and other unnatural
causes may be more likely in this group compared to
general populations, the majority of deaths are in fact
due to preventable physical causes, such as cardiovascu-
lar disease, respiratory disorders, cancers and infectious
disease [6]. In addition, lowered life expectancy may also
be because comorbid substance use disorders (harmful
substance use and dependence) are the most prevalent
psychiatric conditions associated with SMD. Lifetime
alcohol use disorders may affect up to 20% of people
with schizophrenia [7] and between 24 to 35% of people
with bipolar disorders [8, 9]. Comorbid substance use
disorders such as cannabis use disorder [10], opioid and
other drug use disorder are also known to be more
prevalent in these populations compared with the gen-
eral population [9]. Tobacco use has also been noted to
be elevated more than five-fold in people with schizo-
phrenia compared to reference populations [11, 12] and
is a leading preventable cause of death in this group of
people. Global successes in reducing tobacco use in the
general population have not been mirrored by similar re-
ductions in populations with SMD [11, 13].
A history of substance abuse in populations with SMD
has been shown to be associated with an increased risk of
death from all-causes and from unnatural causes [14–16].
In addition, findings from a recent study indicated that in
general, the presence of substance use disorders (across a
broad spectrum of substance types) in SMD was associated
with an increased risk of psychiatric admissions, psychiatric
emergency department presentations and longer in-patient
stays [17]. People with SMDs probably do not just use one
substance in particular but are more likely to engage in
polysubstance use [17]. Factors which make people with
dual diagnoses (comorbid mental and substance use disor-
ders) particularly vulnerable to poor health and social out-
comes, include the mutually detrimental effect on the
course of illness, its identification, diagnosis and treatment;
double stigma and barriers to both mental and physical
health care, as well as the contribution of substance use to
negative health and social outcomes. For tobacco use, the
prevalence of tobacco use in people with SMD is higher,
and people with SMD are known to start smoking earlier
and smoke more heavily [18] compared with the general
population [19]. Potential aetiological pathways for prema-
ture mortality in SMD populations with these comorbidi-
ties are complex and interlinked. Some basic pathways are
summarised in Table 1.
To improve the management of comorbid conditions
in adults with SMD and support the reduction of indi-
vidual health behaviours constituting risk factors for
these illnesses, with the aim of decreasing morbidity and
premature mortality amongst people with SMD, in 2018
the World Health Organization (WHO) launched guide-
lines for the “Management of physical health conditions
in adults with severe mental disorders” [20]. Prior to the
launch of these guidelines it was recognised that whereas
there are WHO guidelines addressing mental and sub-
stance use disorders as well as physical health conditions
in general populations, there was an absence of guidelines
specifically targeting those with SMD having comorbid
conditions. The target audience for the guidelines are
health care practitioners across all specialisms and levels
of health care system, as well as policy makers, healthcare
planners/providers, programme managers, and people liv-
ing with SMD as well as their families and carers, and or-
ganisations representing the interests of people living with
SMD.
In this paper, we present the findings of a detailed
comprehensive overview of existing systematic reviews
on the topic areas of tobacco cessation and management
of comorbid substance use disorder in SMD, which
eventually led to the recommendations in the WHO
guidelines on management of physical health conditions
in adults with severe mental health disorders. The full
guidelines and supporting materials can be accessed
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from the WHO website (https://www.who.int/mental_
health/evidence/guidelines_physical_health_and_severe_
mental_disorders/en/).
Methods
The methodologies used to inform the WHO recom-
mendations for the management of tobacco and sub-
stance use disorders among people with SMD followed
the GRADE (Grading of Recommendations Assessment,
Development and Evaluation) process [21].
A key outcome of the initial phase in developing the
guidelines was in the identification of target areas which
eventually informed the a priori research questions which
followed the PICO [Population, Intervention, Comparison
group, Outcomes] format. The research questions guided
which physical health conditions and risk factors were to be
addressed in the final disseminated guidelines [20]. This
process was informed by scoping reviews and consultation
with a Guideline Development Group (GDG) of externally
appointed international experts, engaged by the WHO. Se-
lected PICO questions reflected areas of uncertainty which
the GDG felt should be prioritised to inform final recom-
mendations. The final research questions for informing sys-
tematic evidence searches were then ratified by the WHO
Guideline Review Committee (GRC), which led to the for-
mulation of specific research questions relevant to tobacco
and substance use disorders among people with SMD (Ta-
bles 2 and 3).
Figure 1 highlights the comprehensive processes which
were followed, leading to the identification of relevant sys-
tematic reviews to inform the research questions relating
to tobacco cessation, and treatment of substance use dis-
orders in SMD. The retrieval, appraisal and synthesis of
evidence closely followed the WHO handbook for guide-
line development [22]. Databases searched included: the
Table 2 Research questions- tobacco use
For people with SMD who use tobacco, are pharmacological (including
nicotine replacement therapy, bupropion, varenicline) and/or non-
pharmacological interventions effective to support tobacco cessation?
Population/ Intervention / Comparison / Outcome (PICO)
Population: People with SMD who use tobacco
Intervention:
• Pharmacological interventions: including nicotine replacement
therapy (NRT), bupropion, varenicline
• Non-pharmacological interventions
Comparison: care as usual and/or placebo
Outcomes:
• Critical
o Tobacco cessation/abstinence rates
o Tobacco consumption rates
o Respiratory disease outcomes (COPD, asthma)
• Important:
o Frequency of adverse events/side-effects
Table 3 Research questions- substance (drug and/ or alcohol)
use disorders
For people with SMD and substance (drug and/or alcohol) use disorder, are
pharmacological and/or non-pharmacological interventions for substance
use disorder effective to support reduction in substance use-related
outcomes?
Population/ Intervention / Comparison / Outcome (PICO)
Population: people with SMD and substance (drug and/or alcohol) use
disorder
Intervention:
pharmacological and/or non-pharmacological interventions for sub-
stance use disorders:
- Pharmacological interventions
- Non-pharmacological interventions: e.g. motivational interviewing
and/or CBT, psychoeducation, brief assessment interview, dual-focus
interventions
Comparison: care as usual / placebo or one treatment vs another
Outcomes:
Critical
- Level of consumption
- Frequency of use
- Abstinence
- Relapse rates
Important:
- Frequency of adverse events / side-effects
Fig. 1 Processes followed to identify direct and indirect evidence for
the PICO questions
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Cochrane Library (including DARE), PubMed/Medline,
Embase, Psychinfo, Epistemonikos and the Global Health
Library. In addition, where searches had to be expanded
(see step 3 in Fig. 1) the National Guideline Clearing
House was also searched. Search terms employed for the
research questions are displayed in supplementary mater-
ial, and reflected the majority of substances listed in chap-
ters F10-F19 of the tenth revision of the International
Classification of Diseases and Related Health Problems
(ICD-10) [23]. (Supplementary material: Table 1); these
were informed through consultation with guideline meth-
odologists and subject-specific experts at the WHO. Sup-
plementary searches highlighting relevant drug-drug
interactions were also employed (Supplementary material:
Table 2). Searches between medicines used for tobacco
cessation or treatment of substance use disorders and
those used for SMDs were carried out using the drug-
drug interaction software Lexi-Interact [24]. Lexi-Interact
was selected for its clinical utility and the fact that it
scored well on both accuracy and comprehensiveness in a
review comparing drug-drug interaction software data-
bases [25]. Searches were performed to February 2018 for
the tobacco PICO question and to June 2018 for the sub-
stance use disorders PICO question.
Systematic reviews selected for inclusion into GRADE ta-
bles conformed to the following inclusion criteria: (1)
Timelines- Published within the last 5 years, preferably
within the last 3 years; (2) Quality- Papers included for
GRADE assessment had sufficiently high methodological
quality ratings on the ‘Assessment of Multiple Systematic
Reviews’ tool (AMSTAR) [26–28] (see below for further de-
tails); (3) Relevance- Retrieved papers were closely relevant
to the PICO population. However, where relevant evidence
could not be identified these criteria were relaxed, leading
to ‘indirect evidence’ to inform recommendations (Fig. 1,
step 3). Cochrane reviews or comprehensive meta-analyses
and systematic reviews were given preference, wherever
possible in this process.
In order to inform the development of evidence based
guidelines in a transparent manner, the GRADE approach
was used [21]. An advantage of GRADE is that the certainty
of the evidence can be summarised and assessment of the
evidence can be separate to the strength of the recommen-
dations which inform the final guidelines [21].
Prior to selection for GRADE assessment, retrieved articles
had to meet sufficiently high quality ratings on the AMSTAR
tool [26–28]. The AMSTAR tool leads to a score across 11
domains according to which the quality of each retrieved sys-
tematic review is rated. Papers were initially assessed by a
member of the team and then cross-checked by another
member of the team (MS, JD, PCG). Systematic reviews ful-
filling inclusion criteria with a sufficiently high AMSTAR
quality rating (a positive rating on more than 6 out of 11 do-
mains) were then assessed using the GRADE approach using
the GRADEpro tool by a member of the team (MS), with all
GRADE assessed papers subsequently rated by a second rater
(JD and CB). Discordant ratings between team members on
the AMSTAR and the GRADE were resolved through dis-
cussion in the team. Key attributes of studies relating to each
of the PICO questions were extracted from each included
study using a structured form by one member of the team
and cross-checked by another. WHO guidelines for rating
studies in terms of certainty of evidence, according to the
GRADE were followed, to assess each study for limitations,
inconsistency, indirectness, imprecision and the reporting of
bias, leading to a final GRADE assessment of the certainty/
confidence of the findings reported in the review [29]. For
each included study a relevant summary measure was ex-
tracted, which was either a Relative Risk (RR) or Mean Dif-
ference (MD).
GRADE evidence profiles for each of the PICOs were
presented and discussed over a series of roundtable
meetings convened at the WHO in Geneva in May 2018.
GDG members were selected internationally across UN
member states for their expertise within the topic areas.
In addition, the meetings were also attended by a guide-
line methodologist, the evidence review team and the
WHO secretariat. The final recommendations resulted
from a consideration of the background evidence for
each of the PICO questions, summarised as GRADE
profiles and the certainty of evidence for these, as well
as taking into consideration other aspects such as
whether the problem was considered a priority, how
substantial desirable and undesirable anticipated effects
were, whether the balance between desirable/undesirable
effects favoured the intervention over the comparator,
the value attached to the outcomes and the certainty of
evidence relating to likely resource requirements, cost
effectiveness, impact on health equity, acceptability and
feasibility of the intervention. In addition the acceptabil-
ity of the intervention to healthcare providers in LMICs,
feasibility of the intervention and the impact of the
intervention on equity and human rights were
considered.
Results
After consultation with the GDG and WHO GRC agreed
research questions specific to tobacco cessation and sub-
stance use disorders were:
1. For people with SMD who use tobacco, are
pharmacological (including nicotine replacement
therapy, bupropion, varenicline) and/or non-
pharmacological interventions effective to support
tobacco cessation?
2. For people with SMD and substance (drug and/or
alcohol) use disorder, are pharmacological and/or
Das-Munshi et al. BMC Psychiatry          (2020) 20:237 Page 6 of 13
non-pharmacological interventions for substance
use disorder effective to support reduction in
substance use-related outcomes?
In total 1434 records were initially identified through
the systematic searches for SMD and tobacco cessation;
after screening for eligibility and removal of duplicates, 4
reviews were included in the GRADE tables for this
PICO with 18 reviews in total contributing evidence
through narrative synthesis. For SMD and substance use
disorders, a total of 4268 records were identified. After
screening and checking against eligibility criteria, 4 stud-
ies were included in the GRADE tables on this topic
with a total of 16 studies included in the narrative syn-
thesis. Figures 2 and 3 display PRISMA flow charts of
relevant articles retrieved for SMD and tobacco use and
with substance use disorders, respectively.
For tobacco use in SMD, GRADE evidence profiles were
compiled for: the use of Buproprion, Varenicline and Nico-
tine Replacement Therapies (NRT) (all versus placebo). In
addition, GRADE profiles for non-pharmacological inter-
ventions (which included: motivational enhancement, psy-
choeducational approaches, Cognitive Behavioural Therapy
(CBT)), supplementing NRT were compared to standard
care approaches, and the use of contingent reinforcement
(using money/money plus NRT) compared to care-as-usual
was assessed with GRADE [30–33] (For full recommenda-
tions with supporting evidence, including relevant drug-
drug interactions for Buproprion, Varenicline and NRT see:
https://www.who.int/mental_health/evidence/guidelines_ph
ysical_health_and_severe_mental_disorders/en/). The GDG
recommended combination pharmacological with behav-
ioural interventions, as behavioural interventions alone have
been shown to result in a relatively low abstinence rate for
tobacco use in SMD.
The certainty of evidence derived from GRADE, relat-
ing to specialised smoking cessation interventions versus
standard approaches in people with SMD, was very low.
There was insufficient evidence to suggest the superior-
ity of specialised smoking interventions over standard
Fig. 2 PRISMA Flow Diagram for systematic review of the reviews: SMD and tobacco cessation
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smoking cessation approaches for SMD populations. In
addition, the certainty of evidence relating to contin-
gency reinforcement approaches compared with care-as-
usual for tobacco cessation in SMD populations was very
low.
Pharmacological interventions identified for tobacco
cessation in SMD populations were: NRT, Bupropion
and Varenicline. Evidence for the efficacy of these interven-
tions in SMD populations mostly derived from high income
settings with a few exceptions (e.g. studies for Bupropion
which had been conducted in China and Iran as well as in
the USA). These pharmacological interventions for tobacco
cessation are already recommended by the WHO in general
populations, although only NRT is on the WHO essential
medicines list [23]. Searches of pharmacological interactions
indicated the possibility of interactions between Bupropion
and psychotropic medications commonly prescribed in
SMD, particularly related to lowering seizure threshold and
enzyme inhibition or induction (see https://www.who.int/
mental_health/evidence/guidelines_physical_health_and_se
vere_mental_disorders/en/for full list of interactions).
For substance use disorders and severe mental disor-
ders, assessment of evidence using the GRADE approach
included a review of evidence relating to psychological in-
terventions such as CBT plus motivation interviewing
(MI) versus care-as-usual, CBT versus care-as-usual, MI
versus care-as-usual and contingency management versus
care-as-usual for people with SMD and substance use dis-
orders [34]. Brief interventions, specifically delivered in
four or fewer sessions [35], were also assessed. Although
these types of interventions may have a basis simply in
providing education and advice [35], the brief interven-
tions which were identified and assessed according to
GRADE for these guidelines all compared motivational
interviewing with CBT approaches, delivered over shorter
time frames [35]. In addition, evidence relating to the effi-
cacy of antipsychotic medications in reducing psychotic
symptoms alongside other outcomes such as frequency of
Fig. 3 PRISMA Flow Diagram for systematic review of the reviews: SMD and substance use disorders
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substance use, in dual diagnoses populations were also
assessed [36, 37] as well the prescribing of antidepressants
in depression comorbid with alcohol use disorders to im-
prove outcomes [38].
All of the main recommendations relating to each of the
PICO questions are presented in Table 4. For dual diagno-
ses populations, there was a lack of evidence to support the
superiority of any of the psychological interventions in im-
proving outcomes related to SMD comorbid with sub-
stance use disorders. Furthermore, the review team were
unable to identify any studies which had specifically
assessed these populations within LMIC settings, further
limiting generalisabilty. Of those studies retrieved, most
were of very low certainty. The GDG reflected that the
Table 4 WHO Recommendations- the management of tobacco use, substance use disorders in people with severe mental disorders
Question Recommendation Strength of recommendation
For people with SMD who use tobacco,
are pharmacological (including nicotine
replacement therapy, bupropion,
varenicline) and/or nonpharmacological
interventions effective to support
tobacco cessation?
In people with severe mental disorders, combined
pharmacological and non-pharmacological
interventions may be considered in accordance
with the WHO training package (Strengthening
health systems for treating tobacco dependence in
primary care. Building capacity for tobacco control:
training package) (http://www. who.int/tobacco/
publications/building_capacity/training_package/
treatingtobaccodependence/en/).
Conditional; quality of evidence- very low
In people with severe mental disorders, a directive
and supportive behavioural intervention
programme may be considered and should be
tailored to the needs of the population.
Conditional; quality of evidence- very low
In people with severe mental disorders, varenicline,
bupropion and nicotine replacement therapy may
be considered for tobacco cessation.
Conditional; quality of evidence- very low
Best practice recommendation Prescribers should take into account potential
interactions between buproprion and varenicline
with psychotropic medications as well as possible
contra-indications.
For people with SMD and substance (drug
and/or alcohol) use disorder, are
pharmacological and/or
non-pharmacological interventions for
substance use disorder effective to support
reduction in substance use-related outcomes?
For people with severe mental disorders and
comorbid substance use disorders (drug and/or
alcohol) interventions should be considered in
accordance with the WHO mhGAP guidelines.
Conditional; quality of evidence- low
Non-pharmacological interventions (e.g.
motivational interviewing) may be considered and
tailored to the needs of people with severe mental
disorders and substance use disorders.
Conditional; quality of evidence- very low
Best practice recommendation Prescribers should take into account the potential
for drug-drug interactions between medicines used
for treatment of substance use disorders and severe
mental disorders.
Additional considerations:
• There was some non-consistent evidence to
indicate effectiveness of motivational interviewing
in reducing cannabis and alcohol use in dual
diagnoses populations in terms of level of
consumption, frequency of use, and abstinence.
• Findings from one study identified from reviews
indicated that contingency management for
substance use may be beneficial in terms of
frequency of use (stimulants and alcohol) and
non-abstinence (stimulants)
• In populations with depression and comorbid
alcohol use disorders there is some indication that
antidepressants may be more effective than
placebo in reducing number of drinks on drinking
days or increasing the number of people abstinent.
• The GDG also highlighted that, for injecting drug
users, testing for Hepatitis B and C and vaccination
for Hepatitis A and B should be considered.
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relative lack of evidence to support the efficacy of these in-
terventions in people with SMD comorbid with substance
use disorders may partly be due to these populations being
more likely to be excluded from research [39].
In general, the assessment of evidence using GRADE
methods indicated low to very low certainty evidence from
randomised controlled trials of pharmacological interven-
tions for the management of mental disorders (whether
through the use of antipsychotics or antidepressants),
which did not indicate the superiority of any of the sur-
veyed medications, when prescribed for people with SMD
comorbid with substance use disorders [36–38]. Moderate
side effects were noted for these interventions, which need
to be taken into account when prescribing for this patient
population. In addition, it was noted that medicines which
may be used for the management of opioid use disorders
such as Methadone and Buprenorphine have interactions
with many of the commonly used psychotropic medica-
tions, including cardiac effects such as QTc prolongation,
central nervous system depression and serotonergic effects
(see Annex 6 of guidelines for details: https://apps.who.int/
iris/bitstream/handle/10665/275718/9789241550383-eng.
pdf?ua=1).
For both comorbid tobacco use and substance use
disorders, where retrieved evidence was of very low
certainty, the expertise of the international GDG was
sought, who applied their expertise to the topic area.
As a result of the low/very low certainty of evidence
retrieved, resultant recommendations were condi-
tional. A ‘conditional’ recommendation by the GDG
indicates that GDG members concluded that benefi-
cial effects of the intervention probably outweighed
undesirable effects but with insufficient evidence for
the GDG to support a ‘strong’ recommendation (with
‘strong’ recommendations indicating that the GDG felt
confident that beneficial effects outweighed undesir-
able effects for the recommended intervention). For
people with SMD and substance (drug and/or alcohol)
use disorder, the low certainty of evidence led to the
recommendation that the mhGAP guidelines for the
management of substance use disorders should be
followed (Table 4).
The full GRADE evidence profiles are displayed in the
supplementary materials (supplementary tables 1–2) and
can also be accessed online. PRISMA checklist has also
been provided in supplementary materials (see additional
material: PRISMA checklist).
Discussion
These evidence-based recommendations, based on de-
tailed and comprehensive reviews of systematic reviews, as
well as consultation with an international body of experts
and WHO specialists, represent a positive and important
step towards tackling the 15–20 year reduction in life
expectancy, experienced by people with SMD compared
to the general population, globally. These guidelines high-
light the need to adequately manage tobacco and other
substance use disorders in people with SMDs, alongside
optimally managing the mental disorder.
Evidence synthesis highlighted a general lack of high-
quality evidence detailing effective interventions for tobacco
cessation in SMD and/or for dual diagnoses populations.
This reflects a systematic exclusion of people with SMD
and/or dual diagnoses from clinical trials, despite evidence
indicating that mental disorders are highly comorbid with
substance use. There is a need to consider and include
these populations in future research [39].
Do the guidelines go far enough? The guidelines retain a
practical emphasis to inform clinicians, healthcare pro-
viders and other professional groups on best-practice rec-
ommendations and acknowledge the importance of wider
multi-level interventional frameworks to address the in-
equalities impacting on SMD populations [40]. Within
this framework, a consideration of health system factors as
well as broader social determinants which include social
support, stigma and attempts to reduce social exclusion
play a major role [40]. In addition, although not directly
addressed by the guidelines, public health actions to pre-
vention implemented at country-level form the backdrop
to recommended interventions at a whole population-
level [41], irrespective of group-specific evidence; for ex-
ample recommended interventions for tobacco cessation
or harmful alcohol use could be read within the context of
country-level increased taxation/pricing policies on to-
bacco or alcohol, restrictions on the availability of alcohol,
measures to restrict drink-driving, restricted tobacco or al-
cohol advertising as well as population-level educational
campaigns on tobacco cessation, and access to screening
and brief interventions [42, 43] or other cost effective in-
terventions [44]. In addition, the guidelines should be read
in conjunction with public health/systemic interventions
at country-level to address and support population-level
mental health [45].
Our searches revealed a scarcity of evidence particu-
larly relating to dual diagnoses populations, which im-
pacted on the ability to make strong recommendations
relevant to people with SMD and comorbid substance
use. The scarcity of good quality evidence to inform the
recommendations reflects the experience of authors of a
previous systematic review, whereby it was found that
more than half of clinical randomised controlled trials
on the pharmacological treatment of opioid dependence
excluded people with psychiatric disorders [39]. The sys-
tematic exclusion of people with mental disorders from
randomised controlled trials has also been noted in one
other review in which the authors assessed the presence
of psychiatric exclusion criteria in randomised controlled
trials [46]. The exclusion of people with mental
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disorders from trials may in part be due to a number of
factors, including trialists’ concerns that decisional cap-
acity to take part is more likely to be impaired in people
with SMDs, or concerns that the stress or unintended
consequence of taking part in a trial may lead to an ex-
acerbation of mental disorder [46]. In addition, pharma-
ceutical companies may stipulate extensive exclusion
criteria to ensure a smoother pathway to regulation and
approval for pharmaceutical products [46]. However,
these practices lead to “scientific neglect” [46], and as we
have highlighted in this paper, serve to perpetuate the
inequalities which people with SMDs experience further.
For those systematic reviews which were retrieved, there
was also an absence of high-quality evidence relating to
psychological interventions to address substance use dis-
orders in dual diagnosis populations. This presents a
major limitation, as there is a high co-morbidity of psy-
chiatric and substance use disorders in clinical practice,
and for practical purposes it is difficult to address one
without the other. In future, research which actively in-
cludes people with SMD and comorbid substance use
are needed particularly to avoid perpetuating further so-
cial exclusion and marginalisation.
Most of the evidence which informed the development
of the guidelines came from well-resourced settings.
This may mean that specific issues relevant to low re-
source settings may impact on implementation. Issues
relating to cost and capacity will need to be taken into
account for some recommended interventions. The
availability of certain medications- such as Varenicline
(which does not currently appear in the WHO essential
medicines list) may be restricted in certain contexts, al-
though other interventions (such as NRT) are more
widely available. Other factors relating to acceptability of
the guidelines and longer term sustainability across
countries will need to be monitored. Future guidelines
may reflect feedback from people on the ground at the
forefront of implementing these guidelines on tobacco
use and substance use disorders in SMDs- for example
following feedback from health care practitioners, policy
makers and public health practitioners.
Conclusions
Tobacco use and substance use disorders play an im-
portant role in heightening the risk of premature mortal-
ity in people with SMDs. Our search of the evidence
highlighted gaps in the evidence base, which may in part
be due to the systematic exclusion of people with SMDs
from clinical trials. Despite the challenges described in this
paper, these guidelines may mark an important step to-
wards addressing premature mortality in people with SMD.
The recommendations may help to inform policy and deci-
sion makers globally and in LMIC settings in ensuring
more equitable access to tobacco cessation and substance
use disorder services for these populations. However the
dearth of high-quality evidence and evidence from LMIC
settings must inform the future research agenda.
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